{"disease":{"id":"lgg","name":"lgg"},"drugs":{"marketed":[{"drug_id":"tovorafenib","indication_name":"relapsed or refractory pediatric low-grade glioma (LGG) harboring a BRAF fusion or rearrangement","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ojemda","generic_name":"TOVORAFENIB","company_name":"Day One Biopharms","drug_phase":"marketed","molecular_target":"","drug_class":"Kinase Inhibitor [EPC]","quality_score":60,"revenue":null,"mechanism":"Ojemda works by blocking the BRAF protein, which is a key driver of cancer cell growth and survival."},{"drug_id":"tovorafenib","indication_name":"relapsed or refractory pediatric low-grade glioma (LGG) harboring a BRAF V600 mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ojemda","generic_name":"TOVORAFENIB","company_name":"Day One Biopharms","drug_phase":"marketed","molecular_target":"","drug_class":"Kinase Inhibitor [EPC]","quality_score":60,"revenue":null,"mechanism":"Ojemda works by blocking the BRAF protein, which is a key driver of cancer cell growth and survival."}],"pipeline":[],"offLabel":[],"totalMarketed":2,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05503797","title":"A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":254,"lead_sponsor_name":"Fore Biotherapeutics","has_results":false},{"nct_id":"NCT05538130","title":"A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":124,"lead_sponsor_name":"Pfizer","has_results":false},{"nct_id":"NCT07004075","title":"FCN-159 Monotherapy Versus Chemotherapy by Investigator's Choice in Pediatric Low-grade Glioma Patients With BRAF Alteration","phase":"PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":102,"lead_sponsor_name":"Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.","has_results":false},{"nct_id":"NCT04201457","title":"A Trial of Dabrafenib, Trametinib and Hydroxychloroquine for Patients With Recurrent LGG or HGG With a BRAF Aberration","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":57,"lead_sponsor_name":"Pediatric Brain Tumor Consortium","has_results":false}],"total":4},"guidelines":[],"source":"Drug Landscape verified database"}